Biosimilars
🇪🇺 EMAEMA news and analysis for pharmaceutical BD, investment, and market access
Track global biosimilar approvals, market entry strategies, and regulatory pathways. Gain critical intelligence for your pharmaceutical BD and investment decisions.
Showing 1–12 of 17 articles
Quick answer
NovaPharmaNews Biosimilars hub for EMA covers 17 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
EMA approved 104 human medicines in 2025: what changed
Eye drugs list: Sodium hyaluronate, tafluprost, tobramycin uses
Biosimilar Approvals: U.S. vs. Europe Insights for Pharma BD
EMA Approves New Medicines in January: Key Updates for Pharma Investors and BD Teams
Global Biosimilar Market Analysis: Trends and Challenges
From Promise to Proof: The Shakeup in Today’s Biosimilar Market
Biosimilar Uptake EU: Market Impact Post-Patent Expirations & HTA Regulation
European Commission Approves POHERDY, First Pertuzumab Biosimilar in Europe by Henlius and Organon
Henlius and Organon's POHERDY Becomes First Pertuzumab Biosimilar Approved in Europe
Biosimilars Growth in EU: Market Forecast Post-Biologics Patent Expiry
Biosimilar Oncology Antibodies: EMA Market Dynamics & Healthcare Impact
Biocon Receives Health Canada Approval for Denosumab Biosimilars Bosaya and Vevzuo
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.